{"organizations": [], "uuid": "bc6262b48a2744c9f1b82fa589e54a36d047d92d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-astellas-pharma-signs-exclusive-li/brief-astellas-pharma-signs-exclusive-licensing-agreement-with-aquinox-pharmaceuticals-idUSL3N1SH17A", "country": "US", "domain_rank": 408, "title": "BRIEF- Astellas Pharma signs exclusive licensing agreement with Aquinox Pharmaceuticals", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-10T04:20:00.000+03:00", "replies_count": 0, "uuid": "bc6262b48a2744c9f1b82fa589e54a36d047d92d"}, "author": "", "url": "https://www.reuters.com/article/brief-astellas-pharma-signs-exclusive-li/brief-astellas-pharma-signs-exclusive-licensing-agreement-with-aquinox-pharmaceuticals-idUSL3N1SH17A", "ord_in_thread": 0, "title": "BRIEF- Astellas Pharma signs exclusive licensing agreement with Aquinox Pharmaceuticals", "locations": [], "entities": {"persons": [{"name": "astellas", "sentiment": "none"}, {"name": "aquinox", "sentiment": "none"}], "locations": [{"name": "asia-pacific", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}, {"name": "europe", "sentiment": "none"}, {"name": "astellas", "sentiment": "none"}, {"name": "north america", "sentiment": "none"}], "organizations": [{"name": "aquinox pharmaceuticals", "sentiment": "negative"}, {"name": "astellas pharma", "sentiment": "negative"}, {"name": "beijing headline news", "sentiment": "none"}, {"name": "aquinox pharmaceuticals reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "astellas pharma inc", "sentiment": "none"}, {"name": "aquinox pharmaceuticals, inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 10(Reuters) - Astellas Pharma Inc\n* Says it signed an exclusive license agreement with Aquinox Pharmaceuticals, Inc for Japan and certain other countries in the Asia-Pacific region for Astellas to develop and commercialize rosiptor, Aquinoxâ€™s lead drug candidate, a first-in-class, once-daily oral treatment currently in Phase 3 clinical development for interstitial cystitis/bladder pain syndrome (IC/BPS) in North America and Europe\n* Under the agreement, Astellas will have the exclusive right to research, develop, and commercialize rosiptor for all human diseases and conditions in Japan and additional countries in the Asia-Pacific region\nSource text in Japanese: goo.gl/rBWrLH\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["https://goo.gl/rBWrLH"], "published": "2018-05-10T04:20:00.000+03:00", "crawled": "2018-05-10T04:39:24.000+03:00", "highlightTitle": ""}